DexCom earnings beat by $0.03, revenue topped estimates
Randall A. Lipps, Chairman, President, and CEO of Omnicell Inc. (NASDAQ:OMCL), recently acquired 10,561 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The shares were purchased at a weighted average price of $33.13, amounting to a total transaction value of $349,874. The purchase price ranged from $32.75 to $33.44 per share. This insider purchase comes as the stock trades near $33, significantly below its 52-week high of $55.74, with InvestingPro analysis suggesting the stock is currently in oversold territory.
In addition to this transaction, Lipps was granted 79,494 restricted stock units at no cost as part of Omnicell’s equity incentive plan. These units will vest gradually, with the first 25% becoming available on March 15, 2026, and the remainder vesting quarterly over the following three years. According to InvestingPro data, Omnicell maintains a strong financial position with a moderate debt level and impressive free cash flow yield of 10%. Discover more insights about OMCL and 1,400+ other stocks through comprehensive Pro Research Reports.
Following these acquisitions, Lipps holds a significant number of shares both directly and in trust, reflecting continued confidence in the company’s prospects. With a market capitalization of $1.54 billion and trading at attractive valuations relative to its growth potential, Omnicell appears positioned for potential upside according to current Fair Value estimates.
In other recent news, Omnicell reported fourth-quarter earnings that surpassed expectations, with adjusted earnings per share at $0.60, exceeding the analyst estimate of $0.58. Revenue for the quarter reached $306.88 million, surpassing the forecast of $299.6 million and marking a 19% year-over-year increase. Despite these strong results, the company’s guidance for the first quarter and full year of 2025 fell short of expectations, with projected first-quarter EPS between $0.15 and $0.25, below the $0.31 consensus, and revenue guidance of $255-265 million missing the $264.9 million analyst estimate at the midpoint.
Omnicell’s Chief Financial Officer, Nchacha Etta, announced his resignation, effective September 15, 2025, or sooner if a successor is appointed. In response, the company has launched a nationwide search for a new CFO. Meanwhile, BofA Securities analyst Allen Lutz reduced the price target for Omnicell shares from $46 to $38, maintaining a Neutral rating. Lutz cited the CFO transition as a potential execution risk but noted the reaffirmed guidance as a positive sign.
Additionally, Omnicell confirmed that Randall A. Lipps will continue as President and CEO through an employment agreement valid until December 31, 2027. This agreement includes an annual base salary of at least $833,000, along with bonuses and long-term incentive awards. Omnicell reiterated its financial guidance for the first quarter and full year of 2025, emphasizing its commitment to strategic priorities and long-term revenue growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.